MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter Read more →
PDS halts work on phase 3 cancer therapy to focus on colorectal contender Read more →
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’ Read more →
